Patient outlook is dependent on the type of alpha-thalassaemia present.
Alpha-thalassaemia silent carriers and patients with alpha-thalassaemia trait are usually asymptomatic and require only education and appropriate genetic counselling.
Patients with haemoglobin H (Hb H) disease have a phenotype of variable severity, although they generally lead normal lives. Patients must be educated about complications (exacerbations of haemolysis, cholelithiasis, ulcers, and growth retardation) and should be monitored as they grow older for the development of iron overload.
Pregnant patients with Hb H disease should be followed carefully for the development of severe anaemia and other complications.
Alpha-thalassaemia major
Without intervention, the fetus is subject to severe hypoxia, leading to hydrops fetalis and the associated morbidity and mortality.[11]Chui DH, Waye JS. Hydrops fetalis caused by alpha-thalassemia: an emerging health care problem. Blood. 1998 Apr 1;91(7):2213-22.
https://ashpublications.org/blood/article/91/7/2213/261092/Hydrops-Fetalis-Caused-by-Thalassemia-An-Emerging
http://www.ncbi.nlm.nih.gov/pubmed/9516118?tool=bestpractice.com
Alpha-thalassaemia major can, however, be associated with survival into childhood if the mother elects to receive intrauterine transfusions (IUT).[37]MacKenzie TC, Amid A, Angastiniotis M, et al. Consensus statement for the perinatal management of patients with alpha thalassemia major. Blood Adv. 2021 Dec 28;5(24):5636-9.
https://ashpublications.org/bloodadvances/article/5/24/5636/477884/Consensus-statement-for-the-perinatal-management
http://www.ncbi.nlm.nih.gov/pubmed/34749399?tool=bestpractice.com
A review of data from the alpha-thalassaemia registry (International Registry of Patients With Alpha Thalassemia) indicates that fetuses with alpha-thalassaemia major who received at least two IUTs had delivery near term, resolution of hydrops, normal neurodevelopmental outcomes, and excellent survival.[96]Schwab ME, Lianoglou BR, Gano D, et al. The impact of in utero transfusions on perinatal outcomes in patients with alpha thalassemia major: the UCSF registry. Blood Adv. 2023 Jan 24;7(2):269-79.
https://ashpublications.org/bloodadvances/article/7/2/269/486857/The-impact-of-in-utero-transfusions-on-perinatal
http://www.ncbi.nlm.nih.gov/pubmed/36306387?tool=bestpractice.com
Case reports and case series report similar outcomes.[97]Kreger EM, Singer ST, Witt RG, et al. Favorable outcomes after in utero transfusion in fetuses with alpha thalassemia major: a case series and review of the literature. Prenat Diagn. 2016 Dec;36(13):1242-9.
http://www.ncbi.nlm.nih.gov/pubmed/27862048?tool=bestpractice.com
[98]Hui PW, Pang P, Tang MHY. 20 years review of antenatal diagnosis of haemoglobin Bart's disease and treatment with intrauterine transfusion. Prenat Diagn. 2022 Aug;42(9):1155-61.
http://www.ncbi.nlm.nih.gov/pubmed/35226373?tool=bestpractice.com
Patients who survive alpha-thalassaemia major in utero will require lifelong transfusion, with the attendant requirement for iron chelation, or will require haematopoietic stem cell transplantation.[37]MacKenzie TC, Amid A, Angastiniotis M, et al. Consensus statement for the perinatal management of patients with alpha thalassemia major. Blood Adv. 2021 Dec 28;5(24):5636-9.
https://ashpublications.org/bloodadvances/article/5/24/5636/477884/Consensus-statement-for-the-perinatal-management
http://www.ncbi.nlm.nih.gov/pubmed/34749399?tool=bestpractice.com